U.S. market Closed. Opens in 9 hours 31 minutes

URGN | UroGen Pharma Ltd. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 12.70 - 13.13
52 Week Range 10.60 - 20.70
Beta 1.11
Implied Volatility 87.35%
IV Rank 15.10%
Day's Volume 477,058
Average Volume 571,830
Shares Outstanding 42,199,400
Market Cap 543,528,272
Sector Healthcare
Industry Biotechnology
IPO Date 2017-05-04
Valuation
Profitability
Growth
Health
P/E Ratio -4.26
Forward P/E Ratio N/A
EPS -3.02
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 203
Country USA
Website URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
*Chart delayed
Analyzing fundamentals for URGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see URGN Fundamentals page.

Watching at URGN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on URGN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙